Clinical Trial News and Research

RSS

Structured setup drives patient engagement with virtual reality therapy

A new study published in JMIR XR and Spatial Computing demonstrates that the way virtual reality therapeutics (VRx) are introduced to patients is a critical factor in how successfully they adopt the technology.

7 Jul 2026

HonorHealth offers new drug that doubles pancreatic cancer survival

Under an FDA ruling that expands access to clinical trials, HonorHealth Research Institute is one of the first in the nation to offer a new drug, Daraxonrasib, that based on early data nearly doubles the average survival time of patients with pancreatic cancer.

7 Jul 2026

Trial supports glargine use in resource-limited Type 1 diabetes care

A trial led by University of Pittsburgh researchers and published today in The Lancet Diabetes & Endocrinology adds nuance to the question of whether older human insulins are as effective as insulin analogues in low-resource settings.

6 Jul 2026

Study identifies promising drug target to prevent neurodegenerative conditions

Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than ten million people worldwide. While current therapies address disease symptoms, they do not prevent the underlying neurodegeneration that drives the disease.

6 Jul 2026

Psychiatry may be moving closer to precision medicine

For decades, treating depression has largely involved a difficult form of medical guesswork: prescribing one antidepressant after another in hopes that one will eventually help.

6 Jul 2026

Anti-lipid antibodies could improve early testing for Lyme disease

Lyme disease can be easiest to treat in its earliest stages, but current tests often miss infections during that critical window and cannot tell whether bacteria are still present or were cleared years ago.

6 Jul 2026

ReproNovo announces first participant dosed in EU Phase 2 trial of RPN-002 for embryo implantation

ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced that the first participant has been dosed in the Company’s EU Phase 2 clinical trial of RPN-002, entitled Nolasiban Optimized Regimen Dosing for Inhibition of Uterine Contractility (NORDIC).

6 Jul 2026

BCG vaccine may remodel the human brain's immune environment

New research led by Mass General Brigham investigators suggests that the Bacillus Calmette-Guérin (BCG) vaccine - which is delivered through the skin to prevent tuberculosis - may remodel the human brain's immune environment, offering a potential biological explanation for previously observed associations between BCG vaccination and lower Alzheimer's disease risk.

6 Jul 2026

Some statins may increase erectile dysfunction risk

Research indicates that certain statins, particularly atorvastatin and simvastatin, may elevate the risk of erectile dysfunction, impacting men's health.

6 Jul 2026

Insilico Medicine highlights AI drug discovery progress at executive summit

Dr. Alex Aliper, Co-founder and President of Insilico Medicine, will attend the AI for Good Global Summit 2026 in Geneva, Switzerland, on July 7.

3 Jul 2026

Feeder-free TIL expansion system makes advanced cancer immunotherapy safer

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

3 Jul 2026

New AI model improves prediction of cancer immunotherapy success

Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some and turning deadly disease into a manageable chronic condition in others.

3 Jul 2026

WHO launches PARTNERS clinical trial for Bundibugyo virus treatments

In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic Republic of the Congo.

3 Jul 2026

Can ibuprofen improve drug-resistant tuberculosis treatment?

While ibuprofen reduced inflammatory markers in drug-resistant TB patients, it did not enhance treatment outcomes, indicating the need for further research.

3 Jul 2026

$Large trial validates dual mobility implants for hip fracture treatment$

Large trial validates dual mobility implants for hip fracture treatment

A major international clinical trial led by Queen Mary University of London and Uppsala University in Sweden has found that an emerging type of hip replacement implant dramatically reduces complications in people with a broken hip.

2 Jul 2026

First-in-class experimental CAR T-cell therapy shows promise against solid tumors

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

2 Jul 2026

Dual-mobility hip implant lowers dislocation risk after replacement surgery

A new type of hip replacement implant reduces the risk of joint dislocation after surgery by 70 per cent. This is the finding of a new study involving 1,600 patients across 44 hospitals in Sweden and the UK, as published in The Lancet.

2 Jul 2026

Tailored drug combinations improve outcomes for treatment-resistant advanced melanoma

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug combinations based on specific tumor biology to improve outcomes for treatment-resistant advanced melanoma.

2 Jul 2026

Low-cost B-cell depleting therapy is as effective as standard treatment for multiple sclerosis

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low-cost B-cell depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS).

2 Jul 2026

Targeted therapy doubles progression-free survival in rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

2 Jul 2026